Argos Therapeutics (ARGS) Getting Somewhat Favorable News Coverage, Analysis Finds

Headlines about Argos Therapeutics (NASDAQ:ARGS) have been trending somewhat positive recently, Accern Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Argos Therapeutics earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 44.5608756144645 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media headlines that may have impacted Accern’s analysis:

Separately, ValuEngine upgraded Argos Therapeutics from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating and three have issued a hold rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $24.00.

Argos Therapeutics (NASDAQ ARGS) traded up $0.01 on Monday, reaching $1.45. The company had a trading volume of 214,300 shares, compared to its average volume of 901,815. Argos Therapeutics has a fifty-two week low of $1.39 and a fifty-two week high of $98.00. The company has a market capitalization of $8.90, a price-to-earnings ratio of -0.06 and a beta of 0.99. The company has a quick ratio of 2.29, a current ratio of 2.29 and a debt-to-equity ratio of -1.46.

TRADEMARK VIOLATION WARNING: This report was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Insider Buying and Selling by Quarter for Argos Therapeutics (NASDAQ:ARGS)

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply